Free Trial
NASDAQ:ADXN

Addex Therapeutics (ADXN) Stock Price, News & Analysis

Addex Therapeutics logo
$8.22 -0.28 (-3.24%)
As of 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Addex Therapeutics Stock (NASDAQ:ADXN)

Key Stats

Today's Range
$8.19
$8.48
50-Day Range
$6.51
$8.19
52-Week Range
$6.51
$13.27
Volume
4,058 shs
Average Volume
92,345 shs
Market Capitalization
$8.72 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$30.00
Consensus Rating
Buy

Company Overview

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder. Addex Therapeutics Ltd has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the discovery, development, and commercialization of novel mGlu2 PAM compounds for the treatment of CNS and related diseases; license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases; and The CharcotMarieTooth Association to evaluate the role of GABAB PAM compounds in preclinical models of CMT1A. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.

Addex Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
33rd Percentile Overall Score

ADXN MarketRank™: 

Addex Therapeutics scored higher than 33% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Addex Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Addex Therapeutics has received no research coverage in the past 90 days.

  • Read more about Addex Therapeutics' stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Addex Therapeutics is -24.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Addex Therapeutics is -24.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Addex Therapeutics has a P/B Ratio of 6.85. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    0.35% of the float of Addex Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Addex Therapeutics has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Addex Therapeutics has recently increased by 45.00%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Addex Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Addex Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.35% of the float of Addex Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Addex Therapeutics has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Addex Therapeutics has recently increased by 45.00%, indicating that investor sentiment is decreasing significantly.
    • Insider Buying vs. Insider Selling

      In the past three months, Addex Therapeutics insiders have not sold or bought any company stock.

    • Percentage Held by Insiders

      15.00% of the stock of Addex Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

    • Percentage Held by Institutions

      Only 16.14% of the stock of Addex Therapeutics is held by institutions.

    • Read more about Addex Therapeutics' insider trading history.
    Receive ADXN Stock News and Ratings via Email

    Sign-up to receive the latest news and ratings for Addex Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

    ADXN Stock News Headlines

    Musk’s Project Colossus could mint millionaires
    I predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.
    See More Headlines

    ADXN Stock Analysis - Frequently Asked Questions

    Addex Therapeutics' stock was trading at $7.00 at the start of the year. Since then, ADXN shares have increased by 17.5% and is now trading at $8.2240.
    View the best growth stocks for 2025 here
    .

    Addex Therapeutics Ltd (NASDAQ:ADXN) posted its quarterly earnings results on Friday, November, 22nd. The company reported ($2.77) earnings per share for the quarter, missing analysts' consensus estimates of ($1.40) by $1.37. Addex Therapeutics had a net margin of 850.30% and a negative trailing twelve-month return on equity of 112.43%.
    Read the conference call transcript
    .

    Shares of Addex Therapeutics reverse split before market open on Monday, October 23rd 2023. The 1-20 reverse split was announced on Monday, October 23rd 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, October 23rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

    Addex Therapeutics' top institutional shareholders include GAMMA Investing LLC (0.83%).

    Shares of ADXN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

    Based on aggregate information from My MarketBeat watchlists, some other companies that Addex Therapeutics investors own include Arista Networks (ANET), Adobe (ADBE), NVIDIA (NVDA), Broadcom (AVGO), GE Aerospace (GE), Vista Energy (VIST) and Arch Capital Group (ACGL).

    Company Calendar

    Last Earnings
    11/22/2024
    Today
    5/21/2025
    Fiscal Year End
    12/31/2025

    Industry, Sector and Symbol

    Stock Exchange
    NASDAQ
    Sector
    Medical
    Industry
    Pharmaceutical preparations
    Sub-Industry
    Pharmaceutical Products
    Current Symbol
    NASDAQ:ADXN
    Employees
    30
    Year Founded
    N/A

    Price Target and Rating

    Average Stock Price Target
    $30.00
    High Stock Price Target
    $30.00
    Low Stock Price Target
    $30.00
    Potential Upside/Downside
    +256.5%
    Consensus Rating
    Buy
    Rating Score (0-4)
    3.00
    Research Coverage
    1 Analysts

    Profitability

    Trailing P/E Ratio
    N/A
    Forward P/E Ratio
    N/A
    P/E Growth
    N/A
    Net Income
    $-11,760,000.00
    Pretax Margin
    -1,106.55%

    Debt

    Sales & Book Value

    Annual Sales
    $556,045.00
    Price / Cash Flow
    N/A
    Book Value
    $1.20 per share
    Price / Book
    7.01

    Miscellaneous

    Free Float
    901,000
    Market Cap
    $8.92 million
    Optionable
    Not Optionable
    Beta
    1.62
    The Next 7 Blockbuster Stocks for Growth Investors Cover

    Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

    Get This Free Report

    This page (NASDAQ:ADXN) was last updated on 5/21/2025 by MarketBeat.com Staff
    From Our Partners